William Blair downgraded shares of Entellus Medical (NASDAQ:ENTL) from an outperform rating to a market perform rating in a research report sent to investors on Friday morning, Marketbeat.com reports.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Entellus Medical from a buy rating to a hold rating in a report on Tuesday, October 31st. Piper Jaffray Companies reissued a buy rating and issued a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub raised Entellus Medical from a hold rating to a buy rating in a report on Saturday, August 19th. ValuEngine raised Entellus Medical from a sell rating to a hold rating in a report on Thursday, December 7th. Finally, Canaccord Genuity reissued a hold rating and issued a $17.00 price objective on shares of Entellus Medical in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $20.40.

Shares of Entellus Medical (NASDAQ ENTL) opened at $24.08 on Friday. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $24.40. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32.

In related news, Director Brian E. Farley sold 40,000 shares of Entellus Medical stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $19.78, for a total value of $791,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of Entellus Medical stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $18.00, for a total value of $36,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 193,469 shares of company stock valued at $4,157,111. 7.70% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Nationwide Fund Advisors boosted its stake in Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 2,635 shares during the period. Bank of America Corp DE boosted its stake in Entellus Medical by 53.8% in the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after purchasing an additional 2,594 shares during the period. First Mercantile Trust Co. boosted its stake in Entellus Medical by 45.3% in the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after purchasing an additional 2,557 shares during the period. JPMorgan Chase & Co. boosted its stake in Entellus Medical by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after purchasing an additional 5,605 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Entellus Medical by 74.7% in the 3rd quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock worth $209,000 after purchasing an additional 4,846 shares during the period. Institutional investors and hedge funds own 78.76% of the company’s stock.

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/entellus-medical-entl-rating-lowered-to-market-perform-at-william-blair/1758725.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.